Sumitomo Pharma Co.ltd. · TSE:4506
Sumitomo Pharma Co.ltd — Corporate Update (January 2011)
12 slides from Sumitomo Pharma Co.ltd's corporate update, Jan 25, 2011
Slide 1: LATUDA Commercial Update
LATUDA Commercial Update LATUDA Meeting (Tokyo) January 2011 Mark Iwicki President and Chief Operating Officer Sunovion Pharmaceuticals Inc.
Slide 2: Sunovion Is Uniquely Positioned to Deliver Strong Performance for LATUDA
Sunovion Is Uniquely Positioned to Deliver Strong Performance for LATUDA Overall market growth is stable and unmet needs remain • Efficacy is key reason to prescribe • High switch and discontinuation rates Strong clinical profile and competitive LATUDA label • Inclusion of olanzapine arm in effi
Slide 3: Atypical Antipsychotic Market Growing at 3%
Atypical Antipsychotic Market Growing at 3% $15.8BN Market Growth in the Atypical Antipsychotic Category Is Being Driven by Use in Bipolar Disorder and Depression 60,000 49MM 50MM 50,000 47MM 2,372 2,373 2,120 DX CAGR 6,644 6,522 5,847 TRx (000s) 40,000 Anxiety 6% 8,647 8,373 9,121 Depression 6% 30,
Slide 4: Monthly Antipsychotic Market TRx Share Trend
Monthly Antipsychotic Market TRx Share Trend Established Market 40% 35% 30% Seroquel 25% Risperidone TRx Share Abilify 20% Zyprexa 15% Geodon 10% Seroquel XR 5% Saphris 0% Fanapt D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N 2007 2008 2009 2010 Source: IMS NPA. The Atypical
Slide 5: Psychiatrists Need New Treatments that Provide a Combination of Strong Efficacy and Tolerability
Psychiatrists Need New Treatments that Provide a Combination of Strong Efficacy and Tolerability Effective in Treating Positive Symptoms 80 Efficacy Effectively controls 53 agitation/aggression Safe for Safety Long-Term Therapy 49 Tolerability Well Tolerated 66 Good patient 49 compliance Does Not Ca
Slide 6: No Single Preferred Agent for Treatment of Schizophrenia
No Single Preferred Agent for Treatment of Schizophrenia All Uses Schizophrenia Uses MAT Sept 2010 MAT Sept 2010 Invega Sustenna Risperdal Risperdal 0.2% FANAPT Saphris Consta 0.5% Invega Invega Sustenna 0.4% Invega 0.1% 0.9% Seroquel XR 3.2% 0.8% Fanapt Saphris 1.8% Clozapine 3.8% 0.2% 0.3% 2.6% Ri
Slide 7: High Discontinuation Rates Create Opportunity for LATUDA
High Discontinuation Rates Create Opportunity for LATUDA CATIE Reinforced Need for New Treatment Options • 74% of patients discontinued the study medication before 18 months Patients dissatisfied with current options • Continue to experience breakthrough symptoms • Discontinue due to adverse “Tw
Slide 8: Leverage Strong Clinical Profile and Positive Label
Leverage Strong Clinical Profile and Positive Label Opportunity to improve value proposition vs. current atypical antipsychotics • Once-daily with food • The recommended starting dose is the therapeutic dose – 40 mg • LATUDA offers proven efficacy with positive cardiometabolic profile • No QTc war
Slide 9: Psychiatrists Are Key Driver for Launch
Psychiatrists Are Key Driver for Launch Schizophrenia Treatment by Specialty A large and stable market with ~2 million patients with PCP & Others, Schizophrenia in the US Neuro 3% 0.5% Our current target audience ~22,000 psychiatrists 336 Sales Force will cover target audience and will be able
Slide 10: Leverage Dedicated and Experienced Sales Force Ready to Deliver on the Potential of LATUDA
Leverage Dedicated and Experienced Sales Force Ready to Deliver on the Potential of LATUDA Sales force: 336 Hospital sales force: 70 Extensive experience selling in the atypical antipsychotic arena Dedicated and qualified Area Medical Specialists team Managed care and Government Affairs te
Slide 11: Sunovion Is Uniquely Positioned to Deliver Strong Performance for LATUDA
Sunovion Is Uniquely Positioned to Deliver Strong Performance for LATUDA Unsatisfied physician and patient population as evidenced by high switch rates creates opportunity for LATUDA LATUDA has a strong clinical profile and competitive label Dedicated and experienced Sales Force ready to compe
Slide 12: Disclaimer Regarding Forward-looking Statements
Disclaimer Regarding Forward-looking Statements The statements made in this presentation material are forward-looking statements based on management’s assumptions and beliefs in light of information available up to the day of announcement, and involve both known and unknown risks and uncertainties.